Share on StockTwits

Galectin Therapeutics (NASDAQ:GALT) Director Arthur Greenberg acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average cost of $4.56 per share, for a total transaction of $4,560.00. Following the transaction, the director now directly owns 96,667 shares in the company, valued at approximately $440,802. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded up 6.33% during mid-day trading on Wednesday, hitting $4.87. 458,874 shares of the company’s stock traded hands. Galectin Therapeutics has a one year low of $4.28 and a one year high of $19.11. The stock’s 50-day moving average is $9.66 and its 200-day moving average is $12.64. The company’s market cap is $107.3 million.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-1.03 EPS for the current fiscal year.

A number of research firms have recently commented on GALT. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.

Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.